ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now?
The scientific landscape surrounding amyotrophic lateral sclerosis (ALS) continues to shift as the number of genes associated with the disease risk and pathogenesis, and the cellular processes involved, continues to grow. Despite decades of intense research and over 50 potentially causative or disea...
Main Authors: | Rita Mejzini, Loren L. Flynn, Ianthe L. Pitout, Sue Fletcher, Steve D. Wilton, P. Anthony Akkari |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-12-01
|
Series: | Frontiers in Neuroscience |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fnins.2019.01310/full |
Similar Items
-
Antisense-mediated splice intervention to treat human disease: the odyssey continues [version 1; peer review: 3 approved]
by: Ianthe Pitout, et al.
Published: (2019-05-01) -
Structural Variants May Be a Source of Missing Heritability in sALS
by: Frances Theunissen, et al.
Published: (2020-01-01) -
Antisense Oligonucleotide-Mediated Terminal Intron Retention of the SMN2 Transcript
by: Loren L. Flynn, et al.
Published: (2018-06-01) -
Targeted <i>SMN</i> Exon Skipping: A Useful Control to Assess In Vitro and In Vivo Splice-Switching Studies
by: Loren L. Flynn, et al.
Published: (2021-05-01) -
Systematic Approach to Developing Splice Modulating Antisense Oligonucleotides
by: May T. Aung-Htut, et al.
Published: (2019-10-01)